Neuroblastoma in older children, adolescents and young adults: A report from the International Neuroblastoma Risk Group project

Pediatric Blood and Cancer

Volumn 61, Issue 4, 2014, Pages 627-635

  Mossé, Yaël P ^a   Deyell, Rebecca J ^b   Berthold, Frank ^c   Nagakawara, Akira ^d   Ambros, Peter F ^e   Monclair, Tom ^f   Cohn, Susan L ^g   Pearson, Andrew D ^h   London, Wendy B ⁱ   Matthay, Katherine K ^j  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF COLOGNE   (Germany)

^d CHIBA CANCER CENTER   (Japan)

^e CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF CHICAGO   (United States)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁱ DANA FARBER HARVARD CANCER CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Adolescents; Autologous hematopoietic cell transplant; Neuroblastoma; Young adults

Indexed keywords

ADOLESCENT; ADULT; AGE CUT OFF; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; EVENT FREE SURVIVAL; EVIDENCE BASED PRACTICE; GENE AMPLIFICATION; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; OVERALL SURVIVAL; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD;

ADOLESCENTS; AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT; NEUROBLASTOMA; YOUNG ADULTS;

ADOLESCENT; ADULT; AGE FACTORS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 11; FEMALE; FOLLOW-UP STUDIES; GENE DELETION; HUMANS; INFANT; INTERNATIONAL AGENCIES; MALE; NEOPLASM GRADING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84893468152     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24777     Document Type: Article

References (27)

1. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol 2010; 28:2625-2634.
2. Esiashvili N, Goodman M, Ward K, et al. Neuroblastoma in adults: Incidence and survival analysis based on SEER data. Pediatr Blood Cancer 2007; 49:41-46.
3. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 2009; 27:289-297.
4. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466-1477.
5. Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: The pediatric oncology group experience-a pediatric oncology group study. J Clin Oncol 1998; 16:2007-2017.
6. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005; 23:6459-6465.
7. Castel V, Villamon E, Canete A, et al. Neuroblastoma in adolescents: Genetic and clinical characterisation. Clin Transl Oncol 2010; 12:49-54.
8. Gaspar N, Hartmann O, Munzer C, et al. Neuroblastoma in adolescents. Cancer 2003; 98:349-355.
9. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224:1121-1124.
10. Christiansen H, Delattre O, Fuchs S, et al. Loss of the putative tumor suppressor-gene locus 1p36 as investigated by a PCR-assay and N-myc amplification in 48 neuroblastomas: Results of the German Neuroblastoma Study Group. Prog Clin Biol Res 1994; 385:19-25.
11. Shapiro DN, Valentine MB, Rowe ST, et al. Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. Am J Pathol 1993; 142:1339-1346.
12. Wada RK, Seeger RC, Brodeur GM, et al. Characterization of human neuroblastoma cell lines that lack N-myc gene amplification. Prog Clin Biol Res 1988; 271:57-69.
13. Shimada H, Chatten J, Newton WA, Jr., et al. Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984; 73:405-416.
14. Gurney JG, Davis S, Severson RK, et al. Trends in cancer incidence among children in the U.S. Cancer 1996; 78:532-541.
15. Blatt J, Gula MJ, Orlando SJ, et al. Indolent course of advanced neuroblastoma in children older than 6 years at diagnosis. Cancer 1995; 76:890-894.
16. Conte M, Parodi S, De Bernardi B, et al. Neuroblastoma in adolescents: The Italian experience. Cancer 2006; 106:1409-1417.
17. Franks LM, Bollen A, Seeger RC, et al. Neuroblastoma in adults and adolescents: An indolent course with poor survival. Cancer 1997; 79:2028-2035.
18. Kushner BH, Kramer K, LaQuaglia MP, et al. Neuroblastoma in adolescents and adults: The Memorial Sloan-Kettering experience. Med Pediatr Oncol 2003; 41:508-515.
19. Tang CK, Hajdu SI. Neuroblastoma in adolescence and adulthood. N Y State J Med 1975; 75:1434-1438.
20. Vandesompele J, Baudis M, De Preter K, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005; 23:2280-2299.
21. Cheung NK, Zhang J, Lu C, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012; 307:1062-1071.
22. Finklestein JZ, Klemperer MR, Evans A, et al. Multiagent chemotherapy for children with metastatic neuroblastoma: A report from Childrens Cancer Study Group. Med Pediatr Oncol 1979; 6:179-188.
23. London W, Castel V, Monclair T, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: A report from the international neuroblastoma risk group project. J Clin Oncol 2011; 29:3286-3292.
24. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005; 353:2243-2253.
25. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341:1165-1173.
26. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-1334.
27. Polishchuk AL, Dubois SG, Haas-Kogan D, et al. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer 2011; 117:4286-4293.